Camrelizumab

Summary

Camrelizumab (CHEMBL4297715) is a phase-3 clinical-stage antibody; indicated across 69 conditions including hepatocellular carcinoma and hodgkins lymphoma; with CIViC clinical evidence for 1 variant-indication association (e.g. TMB Low on-treatment bTMB in lung squamous cell carcinoma).

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 69 conditions
• Clinical trials: 386
• Precision-oncology evidence (CIViC): 1 variant–indication association

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297715
Name	Camrelizumab
Type	Antibody
Max phase	3

Also known as: Camrelizumab, Carilizumab, Carrelizumab, Shr-1210, SHR-1210, CAMRELIZUMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

69 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hepatocellular carcinoma	3	MONDO:0007256	EFO:0000182
Hodgkins lymphoma	3	MONDO:0004952	EFO:0000183
small cell lung carcinoma	3	MONDO:0008433	EFO:0000702
squamous cell lung carcinoma	3	MONDO:0005097	EFO:0000708
carcinoma of esophagus	3	MONDO:0019086	EFO:0002916
non-small cell lung carcinoma	3	MONDO:0005233	EFO:0003060
nasopharyngeal neoplasm	3	MONDO:0005375	EFO:0004252
esophageal squamous cell carcinoma	3	MONDO:0005580	EFO:0005922
gastric adenocarcinoma	3	MONDO:0005036	EFO:0000503
melanoma	3	MONDO:0005105	EFO:0000756
triple-negative breast carcinoma	3	MONDO:0005494	EFO:0005537
gastric neoplasm	3	MONDO:0021085	MONDO:0001056
breast neoplasm	3	MONDO:0021100	MONDO:0007254
head and neck squamous cell carcinoma	3	MONDO:0010150	EFO:0000181
oral cavity squamous cell carcinoma	3	MONDO:0004958	EFO:0000199
squamous cell carcinoma	3	MONDO:0005096	EFO:0000707
exocrine pancreatic carcinoma	3	MONDO:0005192	EFO:0002618
gastric carcinoma	3	MONDO:0004950	EFO:0000178
nasopharyngeal carcinoma	3	MONDO:0015459	MONDO:0015459
clear cell renal carcinoma	2	MONDO:0005005	EFO:0000349
colorectal adenocarcinoma	2	MONDO:0005008	EFO:0000365
lymphoma	2	MONDO:0005062	EFO:0000574
neoplasm	2	MONDO:0005070	EFO:0000616
cervical carcinoma	2	MONDO:0005131	EFO:0001061
acute myeloid leukemia	2	MONDO:0018874	EFO:0000222
osteosarcoma	2	MONDO:0009807	EFO:0000637
sarcoma	2	MONDO:0005089	EFO:0000691
hypopharyngeal carcinoma	2	MONDO:0005216	EFO:0002938
cholangiocarcinoma	2	MONDO:0019087	EFO:0005221
rectal cancer	2	MONDO:0006519	EFO:1000657
adrenal cortex carcinoma	2	MONDO:0006639	EFO:1000796
intrahepatic cholangiocarcinoma	2	MONDO:0003210	EFO:1001961
ovarian cancer	2	MONDO:0008170	MONDO:0008170
lung neoplasm	2	MONDO:0021117	MONDO:0008903
nasal cavity and paranasal sinus lethal midline granuloma	2	MONDO:0006828	MONDO:0019472
urinary bladder neoplasm	2	MONDO:0004987	EFO:0000294
glioblastoma	2	MONDO:0018177	EFO:0000519
soft tissue sarcoma	2	MONDO:0018078	EFO:1001968
colonic neoplasm	2	MONDO:0005401	MONDO:0021063
lung carcinoma	2	MONDO:0005138	EFO:0001071
colorectal neoplasm	2	MONDO:0005335	EFO:0004142
diffuse large B-cell lymphoma	2	MONDO:0018905	EFO:0000403
neuroendocrine carcinoma	2	MONDO:0002120	MONDO:0002120
lung adenocarcinoma	2	MONDO:0005061	EFO:0000571
endometrium neoplasm	2	MONDO:0021251	MONDO:0011962
renal cell carcinoma	2	MONDO:0005086	EFO:0000681
renal cell adenocarcinoma	2	MONDO:0005549	EFO:0005708
endometrial carcinoma	2	MONDO:0002447	EFO:1001512
adenocarcinoma	2	MONDO:0004970	MONDO:0003219
non-Hodgkin lymphoma	1	MONDO:0018908	EFO:0005952
oral cavity neoplasm	1	MONDO:0021245	EFO:0003868
peripheral T-cell lymphoma, not otherwise specified	1	MONDO:0004964	EFO:0000211
pancreatic ductal adenocarcinoma	1	MONDO:0005184	MONDO:0005184

16 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 386.

Phase distribution

Phase	Trials
PHASE2	239
Not specified	42
PHASE3	38
PHASE1/PHASE2	33
PHASE1	21
PHASE2/PHASE3	10
EARLY_PHASE1	2
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06276933	PHASE4	NOT_YET_RECRUITING	A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT04208347	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer
NCT04342910	PHASE3	RECRUITING	Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC
NCT04521153	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma
NCT04639180	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
NCT04803539	PHASE2/PHASE3	RECRUITING	A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC
NCT04944914	PHASE3	RECRUITING	Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma
NCT05043688	PHASE3	RECRUITING	Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC.
NCT05198609	PHASE3	ACTIVE_NOT_RECRUITING	Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial
NCT05320692	PHASE3	ACTIVE_NOT_RECRUITING	A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma
NCT05610332	PHASE3	NOT_YET_RECRUITING	Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes
NCT05613478	PHASE3	RECRUITING	Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma
NCT05738616	PHASE3	RECRUITING	Lenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma (LEN-TAC Study)
NCT05760378	PHASE3	RECRUITING	Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.
NCT05772208	PHASE3	RECRUITING	Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy
NCT05789043	PHASE3	RECRUITING	Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma
NCT05854849	PHASE3	RECRUITING	Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC
NCT05862064	PHASE3	RECRUITING	A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer
NCT06229041	PHASE3	RECRUITING	Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi)
NCT06288373	PHASE2/PHASE3	RECRUITING	Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC
NCT06335355	PHASE2/PHASE3	NOT_YET_RECRUITING	A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients
NCT06438627	PHASE3	RECRUITING	Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial
NCT06485466	PHASE3	RECRUITING	TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma
NCT06889688	PHASE3	RECRUITING	Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician’s Choice Chemotherapy in Advanced Triple-Negative Breast Cancer
NCT07267806	PHASE3	RECRUITING	Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC
NCT07309419	PHASE2/PHASE3	NOT_YET_RECRUITING	A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma
NCT07432087	PHASE3	NOT_YET_RECRUITING	Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT03099382	PHASE3	COMPLETED	Study of SHR-1210 Versus Investigator’s Choice of Chemotherapy for Participants With Advanced Esophageal Cancer
NCT03134872	PHASE3	COMPLETED	A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC
NCT03427827	PHASE3	UNKNOWN	PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma
NCT03605706	PHASE3	UNKNOWN	A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Have Never Received Prior Systemic Treatment.
NCT03668496	PHASE3	UNKNOWN	A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC
NCT03691090	PHASE3	COMPLETED	Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer
NCT03707509	PHASE3	UNKNOWN	Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma
NCT03764293	PHASE3	COMPLETED	A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC
NCT03813784	PHASE3	COMPLETED	A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy
NCT04203485	PHASE3	UNKNOWN	Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)
NCT04342936	PHASE3	UNKNOWN	Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma
NCT04426955	PHASE3	UNKNOWN	Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer
NCT04510610	PHASE2/PHASE3	UNKNOWN	Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

Clinical evidence (CIViC)

Variant × indication × effect (1 predictive associations from 1 curated evidence items):

Variant	Indication	Effect	Therapy	Level	CIViC
TMB Low on-treatment bTMB	Lung Squamous Cell Carcinoma	Sensitivity/Response	Camrelizumab + Carboplatin/Paclitaxel Regimen	CIViC B	EID12919

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).